As California’s legislature heads into its break for the summer, returning on Aug. 21, the top three bills of concern to the life sciences industry all face the potential for amendments before reaching their respective final floor votes.
Update on Key CLSA Federal Policy Activities in Washington, D.C.
The City of South San Francisco continues its economic and population growth at a rapid pace. Construction sites are numerous and further development plans are under consideration.
On July 13, Medicare Trustees released their annual report predicting that, due to slower than expected growth in Medicare spending, the Independent Payment Advisory Board (IPAB) will not be triggered until 2021.
On July 14, 2017, CLSA partnered with Organovo, Takeda and Sanford Burnham Prebys to host a tour for members of the California Legislative Technology and Innovation Caucus.
On June 13, CLSA hosted a roundtable discussion with Los Angeles Mayor Eric Garcetti, CLSA Board Members and other life sciences sector executives from the region to discuss life sciences innovation, investment and job creation.
On June 27, two bills with significant negative consequences for the life sciences industry, Senate Bill 17 (Hernandez) and SB 790 (McGuire), were passed out of California’s Assembly Health Committee.
On June 5, CLSA hosted a congressional briefing on the importance of funding for the National Institutes of Health (NIH) and the Food and Drug Administration (FDA).
CLSA continues to lead efforts to build support within the California congressional delegation for the repeal of two policies that harm life sciences investment and innovation: the medical device tax and Independent Payment Advisory Board (IPAB).
On May 3, 19 members of CLSA’s board of directors spent a full day on Capitol Hill meeting with more than two dozen key members of Congress on issues of importance to California’s life sciences innovation ecosystem.